STAT Plus: Moderna touts research progress as it cuts R&D spending by $1.1 billion
Moderna
Moderna is a biopharmaceutical company based in Cambridge, Mass. Most known for its Covid-19 vaccine, the firm has more than 40 treatment or vaccine candidates in various stages of research or development aimed for use against influenza, Zika, HIV and Epstein–Barr.
Moderna specializes in RNA therapeutics, primarily mRNA vaccines. The name comes from a molecule called messenger RNA (mRNA) that carries instructions for proteins to generate an immune response.
Latest
STAT Plus: Cardiovascular startup raises $260 million led by ex-Moderna execs’ new VC fund
CDC advisory panel opts for a go-slow approach on expanding usage of RSV vaccines
STAT Plus: Former Moderna executive launches genome editing company
STAT Plus: Moderna says data show its combination Covid-flu vaccine generates a strong immune response
STAT Plus: FDA approves Moderna’s RSV vaccine, its second licensed product
STAT Plus: Moderna ends collaboration with CRISPR company Metagenomi, parts ways with gene editing chief
STAT Plus: During the pandemic, were great vaccines bad business? A company-by-company review
All Coverage
advertisement
